231 related articles for article (PubMed ID: 16920892)
1. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
Br J Clin Pharmacol; 2007 Apr; 63(4):469-76. PubMed ID: 17100983
[TBL] [Abstract][Full Text] [Related]
3. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2007 Feb; 47(2):218-26. PubMed ID: 17244773
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
9. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
10. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
11. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
[TBL] [Abstract][Full Text] [Related]
12. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban: a new oral factor Xa inhibitor.
Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
[TBL] [Abstract][Full Text] [Related]
14. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
15. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
16. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
